TESTOSTERONE ENANTHATE 1ml/100 mg
TESTOSTERONE CYPIONATE 1ml/50mg
DROSTANOLONE ENANTHATE 1 ml/ 75 mg
TRENBOLONE HEXABENZYLCARBONATE 1 ml/ 50 mg
Each ml contains:
Testosterone Enanthate USP, 100 mg Testosterone Cypionate 50 mg Drostanolone Enanthate 75 mg Trenbolone Hexabenzylcarbonate 50 mg BP(Vet)
Miglyol 840 Ethyl oleate Benzyl benzoate Benzyl alcohol
BULK 300* is an oil based solution of 4 Steroid compounds for intramuscular injection. BULK 300* is anabolic steroid with significant anabolic and androgenic effects. The Hexahydrobenzylcarbonate release at slow rate, prolong the blood plasma levels of Trenbolone, a continued elevation thereafter for a duration of 7 -10 days. Hexahydrobenzylcarbonate promotes significant increases in strength, muscle anabolism, appetite, and aggression and has been demonstrated to reduce body fat. BULK 300* is suitable for the treatment of hypogonadism and other disorders related to androgen deficiency. BULK 300* has both anabolic and androgenic effects. Testosterone supplementation has been demonstrated to increase strength and growth of new muscle tissue, frequently with increases in libido. Androgens are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.
Testosterone and dihydrotestosterone are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution and have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.
Male hypogonadism results from insufficient secretion of testosterone and is characterized by low serum testosterone concentrations. Symptoms associated with male hypogonadism include decreased sexual desire with or without impotence, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics, and osteoporosis. Hypogonadism is a risk factor for osteoporosis in men. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.
During exogenous administration of androgens, endogenous testosterone release may be inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH). Esterification of testosterone at position 17 increases the lipid solubility of the testosterone molecule and prolongs the activity of the molecule by increasing its residence time. Following intramuscular administration in an oily vehicle, testosterone ester is slowly absorbed into the circulation and rapidly hydrolysed in plasma to testosterone.
In a study of healthy males, a single injection of200 mg of Testosterone Cypionate increased mean serum testosterone concentrations sharply to 3 times the basal levels (approximately 1350 ng/dl) at 24 hours and declined gradually to basal levels (approximately 500 ng/dl) by day 10.
Circulating testosterone is chiefly bound in the serum to sex hormone-binding globulin (SHBG) and albumin. Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are estradiol and dihydrotestosterone. Testosterone is metabolized to DHT by steroid 5- alpha reductase located in the skin, liver, and the urogenital tract of the male. DHT binds with greater affinity to SHBG than does testosterone.
INDICATIONS AND USAGE:
Males: BULK 300* is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired)~testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.
BULK 300* may be used to stimulate puberty in carefully selected males
with clearly delayed puberty that is not secondary to a pathologic disorder,
puberty is expected to occur spontaneously at a relatively late date. Brief
treatment with conservative doses may occasionally be justified in these patients
if they do not respond to psychologic support. The potential adverse effect on
bone maturation should be discussed with the patient and parents prior to
androgen administration. An x-ray of the hand and wrist to determine bone age
should be obtain